March 2021 Publications
- BCG masking phenomena might depend on the species of Mycobacterium. Korablioviene J, Mauricas M, Dumalakiene I, Caplinskas S, Viliene R, Baleisis J, Vysniauskis G, Chorostowska-Wynimko J, Magelinskiene G, Korabliov P, Valiulis A. Acta Microbiol Immunol Hung. 2021 Mar 1. doi: 10.1556/030.2021.01324.
- Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. Pinpathomrat N, Bull N, Pasricha J, Harrington-Kandt R, McShane H, Stylianou E. Vaccine. 2021 Mar 1. doi: 10.1016/j.vaccine.2021.01.034. Epub 2021 Feb 3.
- Clinical use of BCG and its complications: a case series. Colomba C, Rubino R, Mantia G, Marascia FG, Abbott M, Gizzi A, Anastasia A, Palermo G, Tolomeo M, Cascio A, Infez Med. 2021 Mar 1.
- A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line tuberculosis regimen. Chiwala G, Liu Z, Mugweru JN, Wang B, Khan SA, Bate PNN, Yusuf B, Hameed HA, Fang C, Tan Y, Guan P. 2021 biorxiv. Mar 4. doi: 10.1101/2021.03.04.434024.
- Evaluation of a booster tuberculosis vaccine containing mycobacterial DNA-binding protein 1 and CpG oligodeoxynucleotide G9. 1 using a Guinea pig model that elicits immunity to Bacillus Calmette–Guérin. Maeyama J., Iho S, Suzuki F, Hayashi D, Yamamoto T, Yamazaki T, Goto Y, Ozeki Y, Matsumoto S, Yamamoto S. Tuberculosis (Edinb.). 2021 Mar 4. doi: 10.1016/j.tube.2021.102067.
- Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study. Moreira FMF, Verma R, dos Santos PCP, Leite A, da Silva Santos A, de Araujo RCP, da Silva BO, de Sá Queiroz JHF, Persing DH, Södersten E, Gnanashanmugam D. EClinicalMedicine. 2021 Mar 6. doi: 10.1016/j.eclinm.2021.100776.
- A comparative investigation on the role and interaction of EsxA and EsxB in host immune response. Yi Y, Wang H, Su L, Wang H, Zhang B, Su Y. Microb Pathog. 2021 Mar 7. doi: 10.1016/j.micpath.2021.104843.
- BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies. Broset E, Pardo-Seco J, Kanno AI, Aguilo N, Dacosta AI, Rivero-Calle I, Gonzalo-Asensio J, Locht C, Leite LCC, Martin C, Martinón-Torres F. EbioMedicine. 2021 Mar 9. doi: 10.1016/j.ebiom.2021.103254.
- Classical CD4 T cells as the cornerstone of antimycobacterial immunity. Morgan J, Muskat K, Tippalagama R, Sette A, Burel J, Lindestam Arlehamn CS. Immunol Rev. 2021 Mar 9. doi: 10.1111/imr.12963.
- Mapping gene-by-gene single-nucleotide variation in 8,535 Mycobacterium tuberculosis genomes: a resource to support potential vaccine and drug development. Papakonstantinou D, Dunn SJ, Draper SJ, Cunningham AF, O’Shea MK, McNally A. mSphere. 2021 Mar 10. doi: 10.1128/mSphere.01224-20.
- A contained Mycobacterium tuberculosis mouse infection model predicts active disease and containment in humans. Duffy FJ, Olson GS, Gold ES, Jahn A, Aderem A, Aitchison J, Rothchild AC, Diercks AH, Nemeth J. J Infect Dis. 2021 Mar 10. doi: 10.1093/infdis/jiab130.
- Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. Baldwin SL, Reese VA, Larsen SE, Beebe E, Guderian J, Orr MT, Fox CB, Reed SG, Coler RN. PloS One. 2021 Mar 11.. doi: 10.1371/journal.pone.0247990.
- Affordability of adult tuberculosis vaccination in India and China: a dynamic transmission model-based analysis. Weerasuriya CK, Harris RC, Quaife M, McQuaid CF, White RG, Gomez GB. Vaccines (Basel). 2021 Mar 11. doi: 10.3390/vaccines9030245.
- BCG‐induced protection against Mycobacterium tuberculosis infection: evidence, mechanisms, and implications for next‐generation vaccines. Foster M, Hill PC, Setiabudiawan TP, Koeken VA, Alisjahbana B, van Crevel R. Immunol Rev. 2021 Mar 12. doi: 10.1111/imr.12965.
- Macrophage-specific responses to human-and animal-adapted tubercle bacilli reveal pathogen and host factors driving multinucleated cell formation. Queval CJ, Fearns A, Botella L, Smyth A, Schnettger L, Mitermite M, Wooff E, Villarreal-Ramos B, Garcia-Jimenez W, Heunis T, Trost M. PLoS Pathog. 2021 Mar 15. doi: 10.1371/journal.ppat.1009410.
- T cells specific for a mycobacterial glycolipid expand after intravenous Bacillus Calmette–Guérin vaccination. Layton ED, Barman S, Wilburn DB, Krystle, KQ, Smith MT, Altman, JD, Scriba, TJ, Tahiri, N, Minnaard AJ, Roederer M, Seder RA. Epub 2021 J Immunol. 2021 15 Mar. doi: 10.4049/jimmunol.2001065. Epub 2021 Feb 3.
- A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. Woodworth JS, Clemmensen HS, Battey H, Dijkman K, Lindenstrøm T, Laureano RS, Taplitz R, Morgan J, Aagaard C, Rosenkrands I, Arlehamn CSL. bioRxiv. 2021 Mar 18. doi: 10.1101/2021.03.18.435784.
- Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates. Khanna M, Rady H, Dai G, Ramsay AJ. Vaccine. 2021 Mar 19. doi: 10.1016/j.vaccine.2021.01.071. Epub 2021 Feb 23.
- Immune responses following BCG Immunization of infants in Uganda and United Kingdom are similar for purified protein derivative but differ for secretory proteins of Mycobacterium tuberculosis. Mawa PA, Hasso-Agopsowicz M, Lubyayi L, Nabakooza G, Nakibuule M, Blitz R, Dun L, Govind A, Kaleebu P, Webb EL, Elliott AM. Front Immunol. 2021 Mar 19. doi: 10.3389/fimmu.2021.637114.
- Short or long interval between priming and boosting: Does it impact on the vaccine immunogenicity? Pettini E, Pastore G, Fiorino F, Medaglini D, Ciabattini A. Vaccines (Basel). 2021 Mar 20. doi: 10.3390/vaccines9030289.
- Subunit vaccine ESAT-6: c-di-AMP delivered by intranasal route elicits immune responses and protects against Mycobacterium tuberculosis infection. Ning H, Zhang W, Kang J, Ding T, Liang X, Lu Y, Guo C, Sun W, Wang H, Bai Y, Shen L. Front Cell Infect Microbiol. 2021 Mar 22. doi: 10.3389/fcimb.2021.647220.
- Immunogenicity of HspX/EsxS fusion protein of Mycobacterium tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants after subcutaneous administration in animal model. Avarvand AY, Meshkat Z, Khademi F, Tafaghodi M. Microb Pathog. 2021 Mar 21. doi: 10.1016/j.micpath.2021.104842.
- Functional and activation profiles of mucosal-associated invariant T cells in patients with tuberculosis and HIV in a high endemic setting. Balfour A, Schutz C, Goliath R, Wilkinson KA, Sayed S, Sossen B, Kanyik JP, Ward A, Ndzhukule R, Gela A, Lewinsohn DM. Front Immunol. 2021 Mar 22. doi: 10.3389/fimmu.2021.648216.
- A review of the BCG vaccine and other approaches toward tuberculosis eradication. Cho T, Khatchadourian C, Nguyen H, Dara Y, Jung S, Venketaraman V. Human Vaccin Immunother. 2021 Mar 26. doi: 10.1080/21645515.2021.1885280.
- Computational identification of significant immunogenic epitopes of the putative outer membrane proteins from Mycobacterium tuberculosis. Sundar S, Thangamani L, Piramanayagam S. J Genet Eng Biotechnol. 2021 Mar 29. doi: 10.1186/s43141-021-00148-9.
- The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. Tanner R, Hoogkamer E, Bitencourt J, White A, Boot C, Sombroek CC, Harris SA, O’Shea MK, Wright D, Wittenberg R, Sarfas C. F1000Res.2021 Mar 30. doi: 10.12688/f1000research.51640.1.
- Detection of Mycobacterium tuberculosis complex DNA in CD34-positive peripheral blood mononuclear cells of asymptomatic tuberculosis contacts: an observational study. Belay M, Tulu B, Younis S, Jolliffe DA, Tayachew D, Manwandu H, Abozen T, Tirfie EA, Tegegn M, Zewude A, Forrest S. Lancet Microbe. 2021 Mar 31. doi: 10.1016/S2666-5247(21)00043-4.
- The safety of BCG revaccination: A systematic review. Bannister S, Sudbury E, Villanueva P, Perrett K, Curtis N. Vaccine. 2021 Mar 31 doi: 10.1016/j.vaccine.2020.08.016.